1-20 of 32
Paul Smith
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5321: Large scale pan cancer drug combination screening to identify effective and actionable combinations and biomarker hypothesis

Azadeh Bashi, Elizabeth A. Coker, Krishna Bulusu, Marta Milo, Claire Crafter, James Lynch, David Jenkins, Howard Lightfoot, Brandon Willis, Courtney Andersen, Omid Tavana, Kevin Mongeon, Jacob Gordon, Paul Smith, Simon Barry, Ultan McDermott, Lisa Drew, Susan Critchlow, Mathew J. Garnett, Jerome Mettetal
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5321.
https://doi.org/10.1158/1538-7445.AM2023-5321
Published: 04 April 2023
View article titled, Abstract 5321: Large scale pan cancer drug combination screening to identify effective and actionable combinations and biomarker hypothesis
Journal Articles

Abstract 6715: CLIC1 and CLIC4 ion channels as bioelectric targets for tumor treating fields in pediatric high-grade glioma

Michaela Griffin, Paul Smith, Raheela Khan, Surajit Basu, Stuart James Smith
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6715.
https://doi.org/10.1158/1538-7445.AM2023-6715
Published: 04 April 2023
View article titled, Abstract 6715: CLIC1 and CLIC4 ion channels as bioelectric targets for tumor treating fields in pediatric high-grade glioma
Journal Articles

Abstract 4024: Combining selumetinib with BH3 mimetics enhances activity in MAPK-activated acute myeloid leukemia

Courtney L. Andersen, Azadeh Cheraghchi-Bashi, Patricia Jaaks, Elizabeth A. Coker, Kathleen Burke, Justin Cidado, Paul Smith, Corinne Reimer, Raoul Tibes, Mathew Garnett, Jerome Mettetal
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4024.
https://doi.org/10.1158/1538-7445.AM2022-4024
Published: 15 June 2022
View article titled, Abstract 4024: Combining selumetinib with BH3 mimetics enhances activity in MAPK-activated acute myeloid leukemia
Journal Articles

Abstract 1100: Gain and loss of function genome-wide CRISPR screens identify Hippo signaling as an important driver of resistance in EGFR mutant lung cancer

Matthias Pfeifer, Jonathan S. Brammeld, Stacey Price, Matthew Martin, Hannah Thorpe, Aurelie Bornot, Erica Banks, Nin Guan, Shanade Dunn, Maria Luisa Guerriero, Daniel O'Neill, James Pilling, Davide Gianni, James Brownell, Paul Smith, Ultan McDermott
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1100.
https://doi.org/10.1158/1538-7445.AM2021-1100
Published: 01 July 2021
View article titled, Abstract 1100: Gain and loss of function genome-wide CRISPR screens identify Hippo signaling as an important driver of resistance in <em>EGFR</em> mutant lung cancer
Journal Articles

Abstract 1020: Amplification of 22q11 is associated with hypersensitivity to AURKB inhibition in cell line models of resistance to EGFR TKIs

Jordi Bertran-Alamillo, Jon Travers, Ana Giménez-Capitán, Nicolas Floch, Ruth Román, Aisha Swaih, Sonia Rodríguez, Matthew Martin, Erika Aldeguer, Ricardo Miragaia, Josep Castellví, Paul Smith, Alejandro Martínez-Bueno, Elizabeth Pease, Henrik Ditzel, Giulia Fabbri, Rafael Rosell, Urszula Polanska, Miguel A Molina-Vila, Jelena Urosevic
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1020.
https://doi.org/10.1158/1538-7445.AM2021-1020
Published: 01 July 2021
View article titled, Abstract 1020: Amplification of 22q11 is associated with hypersensitivity to AURKB inhibition in cell line models of resistance to EGFR TKIs
Journal Articles

Abstract 3033: Uncovering adaptive mechanisms of resistance to targeted therapy in brain metastasis

Sally J. Adua, Minghui Zhao, Paul Smith, Darren A. Cross, Don X. Nguyen
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3033.
https://doi.org/10.1158/1538-7445.AM2019-3033
Published: 01 July 2019
View article titled, Abstract 3033: Uncovering adaptive mechanisms of resistance to targeted therapy in brain metastasis
Journal Articles

Abstract 5782: Selumetinib-based therapy in uveal melanoma patient-derived xenografts

Didier Decaudin, Rania EL Botty, Béré Diallo, Gerald Massonnet, Justine Fleury, Adnan Naguez, Marine Dubois, Emma J. Davies, Aaron Smith, Joanne Wilson, Colin Howes, Paul Smith, Nathalie Cassoux, Pascale Mariani, Sophie Piperno-Neumann, Sergio Roman Roman, Fariba Nemati
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5782.
https://doi.org/10.1158/1538-7445.AM2018-5782
Published: 01 July 2018
View article titled, Abstract 5782: Selumetinib-based therapy in uveal melanoma patient-derived xenografts
Journal Articles

Abstract 2087: The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma

Béré Diallo, Gerald Massonnet, Rania El-Botty, Chloé Raymondie, Guillaume Carita, Sergio Roman-Roman, Paul Smith, Emma Davies, Didier Decaudin, Fariba Némati
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2087.
https://doi.org/10.1158/1538-7445.AM2016-2087
Published: 15 July 2016
View article titled, Abstract 2087: The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma
Journal Articles

Abstract 908: Identification of novel dynamic biomarkers of FGFR inhibition by the FGFR1,2 and 3 selective inhibitor AZD4547.

Oona Delpuech, Claire Rooney, Lorraine Mooney, Robert McEwen, Sarah Fenton, Dawn Baker, Robert Shaw, Jonathan Dry, Elaine Kilgour, Paul Smith
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 908.
https://doi.org/10.1158/1538-7445.AM2013-908
Published: 15 April 2013
View article titled, Abstract 908: Identification of novel dynamic biomarkers of FGFR inhibition by the FGFR1,2 and 3 selective inhibitor AZD4547.
Journal Articles

Abstract LB-362: The MEK inhibitor selumetinib (AZD6244 - ARRY-142886) prevents lung metastasis in a triple-negative breast cancer (TNBC) xenograft model

Chandra Bartholomeusz, Dadbin Ali, Hitomi Saso, Kimie Kondo, Paul Smith, Gabriel N. Hortobagyi, Naoto T. Ueno
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): LB-362.
https://doi.org/10.1158/1538-7445.AM2012-LB-362
Published: 15 April 2012
View article titled, Abstract LB-362: The MEK inhibitor selumetinib (AZD6244 - ARRY-142886) prevents lung metastasis in a triple-negative breast cancer (TNBC) xenograft model
Journal Articles

Abstract 3256: Sphingolipid regulation by sphingosine kinase anchoring protein (SKAP) and its implication in cancer

Essam A. Ghazaly, Paul Smith, Adedayo Oke, Jackie Perry, Zeinab Al-Shareef, Bryan D. Young, Simon Joel
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3256.
https://doi.org/10.1158/1538-7445.AM2012-3256
Published: 15 April 2012
View article titled, Abstract 3256: Sphingolipid regulation by sphingosine kinase anchoring protein (SKAP) and its implication in cancer
Journal Articles

Abstract 4123: Monocarboxylate transporter 4 expression is a prognostic factor for radiotherapy outcome in squamous cell carcinoma of the head and neck

Amy L. Chadwick, Chris Womack, Gillian Watkins, Becky M. Bola, Nick Slevin, Jarrod Homer, Paul Smith, Susan E. Critchlow, Catharine M. West, Stephen R. Wedge, Ian J. Stratford
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4123.
https://doi.org/10.1158/1538-7445.AM2011-4123
Published: 15 April 2011
View article titled, Abstract 4123: Monocarboxylate transporter 4 expression is a prognostic factor for radiotherapy outcome in squamous cell carcinoma of the head and neck
Journal Articles

Abstract 917: mTOR kinase inhibition relieves feedback inhibition of RTK and PI3K signaling in breast cancer cells

Vanessa S. Rodrik-Outmezguine, Sarat Chandarlapaty, Nen Cao, Paul Smith, Sylvie Guichard, Neal Rosen
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 917.
https://doi.org/10.1158/1538-7445.AM2011-917
Published: 15 April 2011
View article titled, Abstract 917: mTOR kinase inhibition relieves feedback inhibition of RTK and PI3K signaling in breast cancer cells
Journal Articles

Abstract 5038: AZD8055 is an effective inhibitor of mTOR kinase signaling and breast cancer growth while relieving feedback inhibition of HER-kinase signaling

Vanessa S. Rodrik-Outmezguine, Nen Cao, Sarat Chandarlapaty, Qing-Bai She, Qing Ye, Paul Smith, Sylvie Guichard, Neal Rosen
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 5038.
https://doi.org/10.1158/1538-7445.AM10-5038
Published: 15 April 2010
View article titled, Abstract 5038: AZD8055 is an effective inhibitor of mTOR kinase signaling and breast cancer growth while relieving feedback inhibition of HER-kinase signaling
Journal Articles

Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo

Juliane M. Jürgensmeier, Jane Kendrew, Rajesh Odedra, Armelle Logie, Philippa Wood, Paula Valentine, Sharon Barnett, Robert W. Wilkinson, Donald J. Ogilvie, Paul Elvin, Paul Smith, Anderson Ryan, Stephen R. Wedge
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 1372.
https://doi.org/10.1158/1538-7445.AM10-1372
Published: 15 April 2010
View article titled, Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo
Journal Articles

Abstract #3699: High levels of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

Jieru Meng, Herry Peng, Wei Guo, Li Wang, Lin Ji, John Minna, Christine Chresta, Paul Smith, Bingliang Fang, Jack Roth
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3699.
Published: 01 May 2009
View article titled, Abstract #3699: High levels of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)
Journal Articles

Abstract #2742: Activation of FOXO3a by AZD6244 (ARRY-142886) is essential for AZD6244-induced growth suppression in human cancer cells

Jer-Yen Yang, Chun-Ju Chang, Weiya Xia, Paul Smith, Michael Andreeff, Gabriel Hortobagyi, Mien-Chie Hung
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 2742.
Published: 01 May 2009
View article titled, Abstract #2742: Activation of FOXO3a by AZD6244 (ARRY-142886) is essential for AZD6244-induced growth suppression in human cancer cells
Journal Articles

Abstract #3696: AZD8330 (ARRY-424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials

Eli Wallace, Joseph Lyssikatos, James Blake, Allison Marlow, Julie Greschuk, Tammie Yeh, Michele Callejo, Vivienne Marsh, Gregory Poch, Jennifer Otten, Gary Hingorani, Shannon Winski, Deborah Anderson, Patrice Lee, James Winkler, Kevin Koch, Barry Davies, Darren Jones, Armelle Logie, Nicola Curtis, Christine Chresta, Paul Smith, David Robinson
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3696.
Published: 01 May 2009
View article titled, Abstract #3696: AZD8330 (ARRY-424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials
Journal Articles

Abstract #2757: Combination therapy with inhibitors of mTOR and MEK1/2 (AZD6244) kinases, shows enhanced apoptosis and tumor growth inhibition in preclinical models

Robert Wilkinson, Sarah Holt, Nicola Curtis, Armelle Logie, Patrizia Sini, Barry Davies, Christine Chresta, Sylvie Guichard, Paul Smith
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 2757.
Published: 01 May 2009
View article titled, Abstract #2757: Combination therapy with inhibitors of mTOR and MEK1/2 (AZD6244) kinases, shows enhanced apoptosis and tumor growth inhibition in preclinical models
Journal Articles

Activity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in combination with standard and approved therapies: impact of in vivo sequencing of drug administration

Robert Wilkinson, Armelle Logie, Nicola Haupt, Nicola Curtis, Mark Hickinson, Barry Davies, Jennifer McKay, Paul Smith
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4012.
Published: 01 May 2008
View article titled, Activity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in combination with standard and approved therapies: impact of <em>in vivo</em> sequencing of drug administration